Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $13.45. Crescent Biopharma shares last traded at $13.25, with a volume of 61,545 shares.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on CBIO shares. TD Cowen raised shares of Crescent Biopharma to a "strong-buy" rating in a research note on Friday, June 20th. Wedbush assumed coverage on shares of Crescent Biopharma in a research note on Monday, July 14th. They issued an "outperform" rating and a $27.00 target price for the company. Wall Street Zen raised shares of Crescent Biopharma from a "sell" rating to a "hold" rating in a research note on Sunday, July 20th. Stifel Nicolaus assumed coverage on shares of Crescent Biopharma in a research note on Wednesday, June 25th. They issued a "buy" rating and a $28.00 target price for the company. Finally, Lifesci Capital raised shares of Crescent Biopharma to a "strong-buy" rating and set a $22.00 target price for the company in a research note on Wednesday, June 18th. One research analyst has rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $25.67.
View Our Latest Analysis on Crescent Biopharma
Crescent Biopharma Trading Down 1.4%
The company has a market cap of $239.29 million, a P/E ratio of -0.27 and a beta of 1.52.
Crescent Biopharma (NASDAQ:CBIO - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($4.93) EPS for the quarter, missing the consensus estimate of ($2.69) by ($2.24). As a group, equities analysts predict that Crescent Biopharma, Inc. will post -0.16 earnings per share for the current fiscal year.
About Crescent Biopharma
(
Get Free Report)
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Featured Stories
Before you consider Crescent Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.
While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
